Answers are grounded in this paper and cite their sources.
Lateral flow immunoassay (LFIA) is the most widely used platform for point-of-care testing. However, the sensitivity of LFIA remains insufficient for detecting low-abundance biomarkers. In this study, a rod-shaped nanozyme with an osmium-cerium oxide heterojunction (Os-CeO2) was developed to enhance the sensitivity of LFIA. The surfaces of these nanorods were decorated with ultrasmall Os nanoparticles (diameter < 2 nm), which exhibited excellent peroxidase-like activity, enabling the efficient catalytic oxidation of substrates for colorimetric signal generation. The nanozyme was integrated into an LFIA platform (Os-CeO2 LFIA). Compared with conventional gold nanoparticles, the Os-CeO2 LFIA significantly improved the sensitivity. The platform demonstrated high specificity, good stability, and reliable accuracy. These results underscore the strong potential of Os-CeO2 LFIA for clinical analysis, offering a promising strategy to overcome the sensitivity limitations of conventional LFIA for low-abundance biomarker detection.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: